Aerovate Therapeutics

Aerovate Therapeutics

Biotechnology, 930 Winter St Ste M500, Boston, Massachusetts, 02451, United States, 11-50 Employees

aerovatetx.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 61********

Who is AEROVATE THERAPEUTICS

Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial fo...

Read More

map
  • 930 Winter St Ste M500, Boston, Massachusetts, 02451, United States Headquarters: 930 Winter St Ste M500, Boston, Massachusetts, 02451, United States
  • 2018 Date Founded: 2018
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 561110 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from AEROVATE THERAPEUTICS

Aerovate Therapeutics Org Chart and Mapping

Employees

Kylie Troy

Senior Manager, Regulatory Affairs

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Aerovate Therapeutics

Answer: Aerovate Therapeutics's headquarters are located at 930 Winter St Ste M500, Boston, Massachusetts, 02451, United States

Answer: Aerovate Therapeutics's phone number is 61********

Answer: Aerovate Therapeutics's official website is https://aerovatetx.com

Answer: Aerovate Therapeutics's revenue is $1 Million to $5 Million

Answer: Aerovate Therapeutics's SIC: 2834

Answer: Aerovate Therapeutics's NAICS: 561110

Answer: Aerovate Therapeutics has 11-50 employees

Answer: Aerovate Therapeutics is in Biotechnology

Answer: Aerovate Therapeutics contact info: Phone number: 61******** Website: https://aerovatetx.com

Answer: Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access